Welcome to our dedicated page for Viatris SEC filings (Ticker: VTRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viatris Inc. filings document the reporting record of a global healthcare company whose common stock trades on Nasdaq under VTRS. Form 8-K disclosures cover operating results, guidance and material events, including leadership transitions, restructuring actions from an enterprise-wide strategic review, bylaw amendments and shareholder-meeting matters.
Proxy statements describe board oversight, executive compensation, shareholder voting proposals, director nominations and governance practices. The filings also provide formal records for Viatris' capital return activity, strategic priorities, pipeline and product references, and the company's history as the combination of Mylan with Pfizer's Upjohn business.
Viatris Inc director Michael Severino reported equity compensation-related transactions in company stock. On March 6, 2026, 25,112 restricted stock units and 918.455 dividend equivalent units vested and were converted into an equal number of Common Stock shares, leaving him with 26,031 common shares directly held after these acquisitions. The same day, he also received a new award of 15,890 restricted stock units, which are scheduled to vest on March 6, 2027. All activity reflects derivative exercises and grants at a price of $0.00 per unit under the Viatris Inc. 2020 Stock Incentive Plan, with no open-market purchases or sales disclosed.
Viatris Inc executive Andrew Enrietti reported routine equity compensation activity involving restricted stock units (RSUs), dividend equivalent units (DEUs) and related tax withholding. On March 6, 2026, 19,169 RSUs granted on March 6, 2025 vested and were exercised into 19,169 shares of common stock, and 951.6215 DEUs were likewise exercised into 951.6215 shares.
To cover tax liabilities from these vestings, 8,337 and 415 shares of common stock were withheld at $14.16 per share, which is a non‑market disposition rather than an open‑market sale. After these transactions, Enrietti directly held 219,677 shares of Viatris common stock.
He also received a new award of 60,435 RSUs on March 6, 2026, each representing one share of common stock, scheduled to vest in three equal installments of 20,145 RSUs on March 6 of 2027, 2028 and 2029, in addition to remaining unvested RSUs and associated DEUs from the 2025 grant.
PARRISH MARK W reported acquisition or exercise transactions in this Form 4 filing.
Viatris Inc director Mark W. Parrish reported equity compensation activity involving restricted stock units and related common shares. Previously granted RSUs and dividend equivalent units vested into 24,834.4921 shares of common stock on March 6, 2026, and he received a new award of 15,890 RSUs that will vest on March 6, 2027. Following these transactions, he directly holds 165,230 shares of common stock and 15,890 unvested RSUs.
Viatris Inc executive Paul Campbell reported equity compensation activity and related tax withholding in company stock. On March 6, 2026, 27,603 restricted stock units (RSUs) granted on March 6, 2025 vested and were settled into an equal number of common shares, along with 1,370.6231 dividend equivalent units (DEUs) that had accrued on those RSUs.
To cover tax liabilities on these vestings, 12,088 and 601 shares of common stock were withheld at $14.16 per share. Campbell also received a new grant of 56,727 RSUs on March 6, 2026, which will vest in three equal installments of 18,909 RSUs on each of March 6, 2027, March 6, 2028, and March 6, 2029. Following these transactions, he holds 387,638 shares of common stock directly and 318 shares indirectly through a 401(k) plan.
Viatris Inc director MARK RICHARD A reported compensation-related equity activity. On March 6, 2026, previously granted restricted stock units and related dividend equivalent units were exercised, delivering a total of about 24,834 shares of common stock as they vested in full.
The filing also shows a new award of 15,890 restricted stock units, each representing one future Viatris share, scheduled to vest on March 6, 2027. Following these transactions, the director directly holds 116,145 Viatris common shares. All visible derivative awards tied to this filing have now been converted into common stock.
Viatris Inc Chief Executive Officer Scott Andrew Smith reported routine equity compensation activity. On March 6, 2026, 124,519 restricted stock units (RSUs) and 6,181.4237 dividend equivalent units (DEUs) were exercised into common stock, increasing his directly held share count to 1,329,326 shares.
To cover tax liabilities on these vestings, 48,999 and 2,433 shares of common stock were withheld at $14.1600 per share, which are non‑market dispositions. Smith also received a new grant of 256,074 RSUs, scheduled to vest in three equal installments of 85,358 units on March 6 of 2027, 2028, and 2029, and continues to hold 12,362 DEUs tied to earlier awards.
Viatris Inc director Melina E. Higgins reported routine equity compensation activity. On March 6, 2026, she exercised restricted stock units and related dividend equivalent units into a total of 24,834.4921 shares of common stock, reflecting previously vested awards under the company’s stock incentive plan.
On the same date, she received a new grant of 15,890 restricted stock units that will vest on March 6, 2027. Following these transactions, she directly holds 146,048 shares of Viatris common stock and has an additional 74,000 shares reported as indirectly owned through her spouse. These entries are compensation-related acquisitions, not open-market purchases or sales.
Viatris Inc director David S. Simmons reported compensation-related equity activity and small prior share purchases. On March 6, 2026, 22,820 restricted stock units and 523.0399 dividend equivalent units vested and were settled into 23,344 shares of common stock, with fractional shares rounded up under the RSU award terms. On the same date, he received a new grant of 15,890 restricted stock units that will vest on March 6, 2027, each RSU representing one common share.
The filing also shows earlier open-market purchases by family trusts associated with Simmons in 2025, totaling 499 shares of common stock at prices around $10.42 per share. According to the footnotes, these trust purchases were executed by investment advisors in managed accounts designed to mirror certain index funds.
Viatris Inc director Leo Frans Groothuis reported routine equity compensation activity. Restricted stock units and related dividend equivalent units that were previously granted vested and were exercised into common stock on March 6, 2026, with a portion of the resulting shares withheld to cover tax liabilities at $14.16 per share.
On the same date, Groothuis received a new grant of 15,890 restricted stock units, each representing one future share of Viatris common stock that will vest on March 6, 2027. After these vesting, settlement, and tax-withholding transactions, he holds 63,437 shares of Viatris common stock directly.
Viatris Inc director Dillon JoEllen Lyons reported equity compensation activity involving restricted stock units and common shares. On March 6, 2026, previously granted RSUs and related dividend equivalent units representing a total of 24,834.4921 units were exercised, delivering the same number of common shares as they vested in full.
On the same date, Lyons received a new grant of 15,890 RSUs, each representing one future share of Viatris common stock that will vest on March 6, 2027. Following these transactions, she directly holds 102,526 shares of common stock and indirectly holds an additional 18 shares through her spouse.